Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flow from operating activities:
Net loss	$ (28,501)	$ (111,966)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,152	4,685
Non cash lease expense	87	(40)
Provision for doubtful accounts	306	374
Provision for inventory obsolescence	(50)
Change in fair value of warrant liabilities	1,870	(1,601)
Goodwill impairment	0	29,633
IPR&D impairment		107,800
Stock-based compensation expense	5,956	7,844
Change in fair value of contingent consideration		(104,339)
Acquired in-process research and development		3,000
Issuance of common stock for stem-cells to be used in research and development		1,000
Issuance of common stock to Palantir as consideration for settlement agreement	175
Issuance of common stock relating to Yorkville for debt extension and SEPA commitment fee	317
Discounts arising from RWI loan arrangement - related party		2,151
Change in fair value of contingent stock consideration		(120)
Loss on extinguishment of debt	3,908	0
Change in fair value of debt	(14)	2,357
Non cash interest expense	2,310
Other, net	(286)	876
Changes in assets and liabilities:
Accounts receivable	(3,732)	1,266
Inventory	5,150	(2,820)
Prepaid expenses and other assets	850	2,981
Accounts payable	(397)	6,043
Accrued expenses and other liabilities	3,159	645
Accrued R&D software	(3,500)	23,917
Lease liabilities - operating	179	117
Deferred revenue	210	175
Net cash used in operating activities	(7,851)	(26,022)
Cash flow from investing activities:
Capital expenditures	(70)	(240)
Proceeds from Sanuwave convertible note receivable	2,175
Purchase of acquired in-process research and development		(3,000)
Net cash provided by (used in) investing activities	2,105	(3,240)
Cash flow from financing activities:
Proceeds from warrants and short-term debt - related parties	15,000	17,369
Proceeds from registered direct offering		6,000
Proceeds from the exercise of stock options		304
Repayments of short-term debt - unaffiliated	(17,374)	(16,811)
Proceeds from issuance of short-term debt - unaffiliated	2,993
Payment of SEPA commitment fee	(25)
Repayments of short-term debt - related parties	(100)
Proceeds from PIPE financing	6,000	12,750
Proceeds from the sale of common stock in ATM offering		136
Payments of PIPE and other issuance costs		(1,293)
Tax withholding on vesting of restricted stock units	(357)	(86)
Net cash provided by financing activities	6,137	18,369
Net increase (decrease) in cash, cash equivalents and restricted cash	391	(10,893)
Cash, cash equivalents and restricted cash at beginning of period	10,163	28,802
Cash, cash equivalents and restricted cash at end of period	10,554	17,909
Supplemental disclosure of cash flow information:
Cash paid for interest	144	1,073
Supplemental non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses	(21)	(1,010)
Modification of C.V. Starr warrants in connection with forbearance	51
Issuance of RWI warrants in connection with forbearance	$ 1,162
Issuance of warrants on senior secured bridge loan		2,002
PIPE related costs included in accrued expenses		(69)
Common stock issued for short-term debt conversion		3,792
Interest accrued on senior secured loans within long-term debt - related parties		$ (307)